Page last updated: 2024-10-26

valproic acid and Acrania

valproic acid has been researched along with Acrania in 125 studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Research Excerpts

ExcerptRelevanceReference
" However, a particular association of valproate and carbamazepine with neural tube defects (NTDs)--specifically, with spina bifida aperta (SB)--has been identified."8.82Management issues for women with epilepsy: neural tube defects and folic acid supplementation. ( Yerby, MS, 2003)
"Administration of the antiepileptic drug valproic acid (VPA) during early pregnancy can result in a 1-2% incidence of spina bifida aperta, a closure defect of the posterior neural tube in the human."8.78Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. ( Ehlers, K; Hauck, RS; Nau, H, 1991)
"Valproic acid (VPA), a widely prescribed antiepileptic drug and an effective treatment for psychiatric disorders, is teratogenic causing neural tube defects (NTDs) and other defects in the exposed embryo."7.96Gestational exposure to valproic acid upregulates total Stat3 protein expression while downregulating phosphorylated Stat3 in CD-1 mouse embryos with neural tube defects. ( Shafique, S; Winn, LM, 2020)
" High dose valproic acid led to significantly higher number of embryos with neural tube defects compared to low-dose valproic acid (p = 0."7.91Valproic acid effect on neural tube defects is not prevented by concomitant folic acid supplementation: Early chick embryo model pilot study. ( Cakin, H; Kazan, S; Ozak, A; Turgut, U, 2019)
" Using the prenatal valproic acid (VPA)-injection model of autism spectrum disorder (ASD) in rats, which produces social impairrment and altered seizure susceptibility as in human ASD patients as well as mild neural tube defects like crooked tail phenotype, we examined whether chronic administration of red ginseng extract may rescue the social impairment and crooked tail phenotype in prenatally VPA-exposed rat offspring."7.79Effects of Korean red ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid. ( Han, SH; Kim, HJ; Kim, HY; Kim, KC; Kim, P; Kwon, KJ; Lee, JM; Park, JH; Shin, CY, 2013)
"Valproic acid (VPA) is a potent inducer of neural tube defects in human and mouse, its teratogenicity is associated with its potential to generation of free radicals and increase oxidative stress."7.78Spirulina (arthrospira) protects against valproic acid-induced neural tube defects in mice. ( Chamorro-Cevallos, G; Escalona-Cardoso, GN; Paniagua-Castro, N; Pérez-Pastén, R, 2012)
" Administration of valproic acid (VA) during first trimester of pregnancy causes neural tube defects (NTDs)."7.78Reduction in valproic acid-induced neural tube defects by maternal immune stimulation: role of apoptosis. ( Hrubec, T; Mallela, M, 2012)
"Exposure to the anticonvulsant valproic acid (VPA) during the first trimester of pregnancy is associated with an increased risk of congenital malformations including heart defects, craniofacial abnormalities, skeletal and limb defects, and, most frequently, neural tube defects (NTDs)."7.77Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. ( Tung, EW; Winn, LM, 2011)
"Valproic acid is a commonly prescribed antiepileptic agent that causes birth defects including neural tube defects."7.77Valproic acid-induced DNA damage increases embryonic p27(KIP1) and caspase-3 expression: a mechanism for valproic-acid induced neural tube defects. ( Tung, EW; Winn, LM, 2011)
" Maternal treatment with valproic acid (VPA) during pregnancy induces NTD in susceptible fetuses."7.73Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos. ( Benedict, S; Nagelkerke, N; Padmanabhan, R; Shafiullah, M, 2006)
"Valproic acid, a commonly used antiepileptic agent, is associated with a 1 to 2% incidence of neural tube defects when taken during pregnancy; however, the molecular mechanism by which this occurs has not been elucidated."7.73Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. ( Defoort, EN; Kim, PM; Winn, LM, 2006)
"In utero exposure to valproic acid (VPA) during pregnancy is associated with an increased risk of neural tube defects (NTDs)."7.73Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. ( Dawson, JE; Raymond, AM; Winn, LM, 2006)
" Periconceptional folic acid supplementation is reported to protect embryos from developing neural tube defects (NTD)."7.72Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. ( Padmanabhan, R; Shafiullah, MM, 2003)
"Neural tube defects (NTDs) are the most common of the major anomalies associated with in utero exposure to valproic acid."7.70Safe use of valproic acid during pregnancy. ( Kennedy, D; Koren, G, 1999)
"Neural tube defects were induced dose-dependently by single injections of the anticonvulsant drug valproic acid (VPA) as sodium salt in mice on gestational day 8."7.67Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse. ( Nau, H; Trotz, M; Wegner, C, 1987)
"The teratogenic effects of valproic acid and its 4-propyl-4-pentenoic acid (4-en) metabolite were investigated in three inbred mouse strains that were known to possess differing sensitivity to heat-induced neural tube defects."7.67Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. ( Bennett, GD; Finnell, RH; Karras, SB; Mohl, VK, 1988)
"Exposure in pregnancy is associated with approximately three-fold increase in the rate of major anomalies, mainly spina bifida and only rarely anencephaly (NTD), cardiac, craniofacial, skeletal and limb defects and a possible set of dysmorphic features, the "valproate syndrome" with decreased intrauterine growth."6.45Valproic acid in pregnancy: how much are we endangering the embryo and fetus? ( Ornoy, A, 2009)
"Epilepsy is a common medical problem and many studies have demonstrated that infants of women with epilepsy (WWE) have a two to threefold higher risk of congenital malformations compared with the background population."6.43Recent advances on neural tube defects with special reference to Valproic Acid. ( Chiarelli, F; Latini, G; Pelliccia, P; Tana, M; Verrotti, A, 2006)
" An appropriate dosing regimen (consecutive doses of VPA on Day 9 of gestation) can also result in a low incidence of spina bifida aperta and a high incidence of spina bifida occulta in the mouse."6.39Valproic acid-induced neural tube defects. ( Nau, H, 1994)
"PTA significantly reduced VPA-induced exencephaly, while none of the other external malformations such as open eyelid or skeletal malformations such as fused, absent, or bifurcated ribs and fused thoracic vertebrae and fused sternebrae were reduced."5.29Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). ( Nagao, T; Sato, M; Shirota, M, 1995)
"Fetuses were examined for exencephaly, resorption, and fetal weight retardation on day 18 of gestation."5.28Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. ( Elmazar, MM; Nau, H, 1992)
" In the general population, it is well established that periconceptual folic acid reduces the risk of neural tube defects (NTDs) and possibly other congenital abnormalities."5.05Valproate and folate: Congenital and developmental risks. ( Green, R; Reynolds, EH, 2020)
"Valproic acid (VPA) use during pregnancy increases fetal risk of major congenital malformations and cognitive impairment."4.93Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review. ( Gotlib, D; Kurlander, J; Muzik, M; Perelstein, E; Riba, M; Zivin, K, 2016)
" However, a particular association of valproate and carbamazepine with neural tube defects (NTDs)--specifically, with spina bifida aperta (SB)--has been identified."4.82Management issues for women with epilepsy: neural tube defects and folic acid supplementation. ( Yerby, MS, 2003)
"Administration of the antiepileptic drug valproic acid (VPA) during early pregnancy can result in a 1-2% incidence of spina bifida aperta, a closure defect of the posterior neural tube in the human."4.78Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. ( Ehlers, K; Hauck, RS; Nau, H, 1991)
"Chemotherapeutic agents such as methotrexate (MTX), raltitrexed (RTX), 5-fluorouracil (5-FU), hydroxyurea (HU), and retinoic acid (RA), and valproic acid (VPA), an antiepileptic drug, all can cause malformations in the developing central nervous system (CNS), such as neural tube defects (NTDs)."4.12Unraveling the Mechanisms of Clinical Drugs-Induced Neural Tube Defects Based on Network Pharmacology and Molecular Docking Analysis. ( Guan, Z; Li, S; Liang, Y; Niu, B; Wang, J; Wang, X; Yang, A; Yu, J; Zhu, Z, 2022)
"Fetal exposure to the anticonvulsant drug valproic acid (VPA), used to treat certain types of epilepsy, increases the risk for birth defects, including neural tube defects, as well as learning difficulties and behavioral problems."4.02Folic acid supplementation rescues valproic acid-induced developmental neurotoxicity and behavioral alterations in zebrafish embryos. ( Bondesson, M; Garyfalidis, E; Gustafsson, JÅ; Kondamadugu, VS; Muhsen, M; Riu, A; Youngs, J, 2021)
"Valproic acid (VPA), a widely prescribed antiepileptic drug and an effective treatment for psychiatric disorders, is teratogenic causing neural tube defects (NTDs) and other defects in the exposed embryo."3.96Gestational exposure to valproic acid upregulates total Stat3 protein expression while downregulating phosphorylated Stat3 in CD-1 mouse embryos with neural tube defects. ( Shafique, S; Winn, LM, 2020)
" High dose valproic acid led to significantly higher number of embryos with neural tube defects compared to low-dose valproic acid (p = 0."3.91Valproic acid effect on neural tube defects is not prevented by concomitant folic acid supplementation: Early chick embryo model pilot study. ( Cakin, H; Kazan, S; Ozak, A; Turgut, U, 2019)
" This limitation and high risks of neural tube and other major teratogenic effects, especially of valproate, indicate the need for great caution in the use of valproate and carbamazepine to treat bipolar disorder in women of child-bearing age."3.88Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary. ( Baldessarini, RJ; Patel, N; Viguera, AC, 2018)
" Using the prenatal valproic acid (VPA)-injection model of autism spectrum disorder (ASD) in rats, which produces social impairrment and altered seizure susceptibility as in human ASD patients as well as mild neural tube defects like crooked tail phenotype, we examined whether chronic administration of red ginseng extract may rescue the social impairment and crooked tail phenotype in prenatally VPA-exposed rat offspring."3.79Effects of Korean red ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid. ( Han, SH; Kim, HJ; Kim, HY; Kim, KC; Kim, P; Kwon, KJ; Lee, JM; Park, JH; Shin, CY, 2013)
" Administration of valproic acid (VA) during first trimester of pregnancy causes neural tube defects (NTDs)."3.78Reduction in valproic acid-induced neural tube defects by maternal immune stimulation: role of apoptosis. ( Hrubec, T; Mallela, M, 2012)
"Valproic acid (VPA) is a potent inducer of neural tube defects in human and mouse, its teratogenicity is associated with its potential to generation of free radicals and increase oxidative stress."3.78Spirulina (arthrospira) protects against valproic acid-induced neural tube defects in mice. ( Chamorro-Cevallos, G; Escalona-Cardoso, GN; Paniagua-Castro, N; Pérez-Pastén, R, 2012)
" Microarray studies in P19 mouse embryocarcinoma cells and mouse embryos have indicated that valproic acid (VPA), an inducer of neural tube defects, deregulates the expression of many genes, including those critically involved in neural tube development."3.77Short-time gene expression response to valproic acid and valproic acid analogs in mouse embryonic stem cells. ( Dencker, L; Forsberg, M; Gustafson, AL; Jergil, M; Salter, H; Stigson, M; Stockling, K, 2011)
"Exposure to the anticonvulsant valproic acid (VPA) during the first trimester of pregnancy is associated with an increased risk of congenital malformations including heart defects, craniofacial abnormalities, skeletal and limb defects, and, most frequently, neural tube defects (NTDs)."3.77Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. ( Tung, EW; Winn, LM, 2011)
"Prenatal exposure to valproic acid (VPA) induces neural tube defects and impairment in social behaviors related to autistic spectrum disorder in newborns, which make it a useful animal model of autism."3.77The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. ( Cheong, JH; Choi, CS; Go, HS; Kim, KC; Kim, P; Ko, KH; Shin, CY; Yang, SI, 2011)
"Valproic acid is a commonly prescribed antiepileptic agent that causes birth defects including neural tube defects."3.77Valproic acid-induced DNA damage increases embryonic p27(KIP1) and caspase-3 expression: a mechanism for valproic-acid induced neural tube defects. ( Tung, EW; Winn, LM, 2011)
"Exposure to the anticonvulsant drug valproic acid (VPA) in utero is associated with a 1-2% increase in neural tube defects (NTDs), however the molecular mechanisms by which VPA induces teratogenesis are unknown."3.76Epigenetic modifications in valproic acid-induced teratogenesis. ( Tung, EW; Winn, LM, 2010)
" We point out that during the pregnancy 4 of these 5 women with epilepsy had taken valproates, and the other one--carbamazepine."3.75[Fetal malformations in women with epilepsy]. ( Bozhinov, P; Bozhinova, C; Markova, C, 2009)
"Folic acid supplementation reduces the occurrence of neural tube defects (NTDs); however, it is not clear whether it protects against teratogenic effects of antiepileptic drugs."3.74Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect. ( Boisson, C; Candito, M; Gaucherand, P; Guéant, JL; Luton, D; Naimi, M; Rudigoz, JC; Van Obberghen, E, 2007)
"Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population."3.73Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma. ( Holladay, SD; Hrubec, TC; Salafia, CM; Yan, M; Ye, K, 2006)
"In utero exposure to valproic acid (VPA) during pregnancy is associated with an increased risk of neural tube defects (NTDs)."3.73Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. ( Dawson, JE; Raymond, AM; Winn, LM, 2006)
"Structure-activity relationship studies of valproic acid (VPA) derivatives have revealed a quantitative correlation between histone deacetylase (HDAC) inhibition and induction of neural tube defects (NTDs) in the NMRI-exencephaly-mouse model, but this correlation has been, so far, limited to congeners with a carboxylic acid function."3.73S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates an ( Eikel, D; Hoffmann, K; Lampen, A; Nau, H; Zoll, K, 2006)
"Valproic acid, a commonly used antiepileptic agent, is associated with a 1 to 2% incidence of neural tube defects when taken during pregnancy; however, the molecular mechanism by which this occurs has not been elucidated."3.73Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. ( Defoort, EN; Kim, PM; Winn, LM, 2006)
" Maternal treatment with valproic acid (VPA) during pregnancy induces NTD in susceptible fetuses."3.73Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos. ( Benedict, S; Nagelkerke, N; Padmanabhan, R; Shafiullah, M, 2006)
" Periconceptional folic acid supplementation is reported to protect embryos from developing neural tube defects (NTD)."3.72Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. ( Padmanabhan, R; Shafiullah, MM, 2003)
"In the current study, we wanted to extend our findings and test the hypothesis that Folbp2(-/-) mice are more susceptible to the teratogenic effects of valproic acid (VPA), a commonly used antiepileptic drug that is known to induce neural tube defects (NTDs) in both humans and laboratory animals."3.72Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice. ( Finnell, RH; Merriweather, MY; Spiegelstein, O; Wicker, NJ, 2003)
" The antiepileptic drug valproic acid (VPA) is a potent inducer of neural tube defects (NTDs) in human and mouse embryos."3.72Valproic acid teratogenicity: a toxicogenomics approach. ( Dencker, L; Gustafson, AL; Kultima, K; Nyström, AM; Scholz, B; Stigson, M, 2004)
"Clinical and epidemiologic studies have indicated that maternal use of valproic acid during early pregnancy causes an increased risk for spina bifida."3.70Developmental toxicity of valproic acid during embryonic chick vertebral chondrogenesis. ( Basu, A; Wezeman, FH, 2000)
"Teratogenic chemicals (2,3,7, 8-tetrachlorodibenzo-p-dioxin [TCDD], ethyl carbamate [urethane], methylnitrosourea [MNU], or valproic acid [VA]) were given to pregnant mice to induce cleft palate (TCDD, urethane), digital defects (urethane, MNU), or exencephaly (VA)."3.70Nonspecific stimulation of the maternal immune system. I. Effects On teratogen-induced fetal malformations. ( Blaylock, BL; Gogal, RM; Holladay, SD; Sharova, L; Smith, BJ; Ward, DL, 2000)
"Neural tube defects (NTDs) are the most common of the major anomalies associated with in utero exposure to valproic acid."3.70Safe use of valproic acid during pregnancy. ( Kennedy, D; Koren, G, 1999)
"Ingestion of the anticonvulsant drug valproic acid and of the angiotensin converting enzyme inhibitor captopril during pregnancy has been associated with abnormal fetal outcome in humans."3.69Evaluation of the rat embryo culture system as a predictive test for human teratogens. ( Buttar, HS; Guest, I; Smith, S; Varma, DR, 1994)
" In a search for protection against neural tube defects, we investigated the effect of methionine on the incidence of VPA-induced spina bifida in the mouse."3.69Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics. ( Ehlers, K; Elmazar, MM; Nau, H, 1996)
"The molecular basis for the well-established hierarchy of susceptibility to valproic acid-induced neural tube defects in inbred mouse strains was examined using in situ transcription and anti-sense RNA amplification methodologies with both univariate and multivariate analyses of the resulting gene expression data."3.69Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. ( Bennett, GD; Craig, JC; Finnell, RH; Piedrahita, JA; Wlodarczyk, BC, 1997)
"The anticonvulsant drug valproic acid (VPA) is suspected to be a developmental toxicant in humans, inducing primarily neural tube defects."3.68Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro. ( Grafton, TF; Hansen, DK, 1991)
" Before 1000 when the ratios of folate metabolites were stable, the rate of valproic acid-induced neural tube defects was reduced from 49% of living fetuses to 12% by coapplication of folinic acid via subcutaneously implanted minipumps."3.68Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent. ( Nau, H; Wegner, C, 1991)
"Fetal exposure to valproic acid has recently been associated with an increased incidence of neural tube defects."3.67Prenatal detection of a neural tube defect after fetal exposure to valproic acid. ( Campbell, WA; Cassidy, SB; Ciarleglio, L; Nochimson, DJ; Vintzileos, AM; Weinbaum, PJ, 1986)
"Neural tube defects were induced dose-dependently by single injections of the anticonvulsant drug valproic acid (VPA) as sodium salt in mice on gestational day 8."3.67Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse. ( Nau, H; Trotz, M; Wegner, C, 1987)
"The teratogenic effects of valproic acid and its 4-propyl-4-pentenoic acid (4-en) metabolite were investigated in three inbred mouse strains that were known to possess differing sensitivity to heat-induced neural tube defects."3.67Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. ( Bennett, GD; Finnell, RH; Karras, SB; Mohl, VK, 1988)
"Exposure in pregnancy is associated with approximately three-fold increase in the rate of major anomalies, mainly spina bifida and only rarely anencephaly (NTD), cardiac, craniofacial, skeletal and limb defects and a possible set of dysmorphic features, the "valproate syndrome" with decreased intrauterine growth."2.45Valproic acid in pregnancy: how much are we endangering the embryo and fetus? ( Ornoy, A, 2009)
"Epilepsy is a common medical problem and many studies have demonstrated that infants of women with epilepsy (WWE) have a two to threefold higher risk of congenital malformations compared with the background population."2.43Recent advances on neural tube defects with special reference to Valproic Acid. ( Chiarelli, F; Latini, G; Pelliccia, P; Tana, M; Verrotti, A, 2006)
"Neural tube defects were seen in 3% of the sample."2.41Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. ( Kozma, C, 2001)
" An appropriate dosing regimen (consecutive doses of VPA on Day 9 of gestation) can also result in a low incidence of spina bifida aperta and a high incidence of spina bifida occulta in the mouse."2.39Valproic acid-induced neural tube defects. ( Nau, H, 1994)
"Neural tube defects (NTDs), including anencephaly and spina bifida, are common major malformations of fetal development resulting from incomplete closure of the neural tube."1.91A Shared Pathogenic Mechanism for Valproic Acid and ( Huang, J; Luo, J; Parent, JM; Sexton, JZ; Sudyk, R; Takla, TN; Tidball, AM; Vora, NL; Walker, JC, 2023)
"Valproic acid (VPA) is a widely prescribed drug to treat epilepsy, bipolar disorder, and migraine."1.72Aberrant induction of p19Arf-mediated cellular senescence contributes to neurodevelopmental defects. ( Keyes, WM; Klein, A; Knauer-Meyer, T; Plassat, JL; Rhinn, M; Zapata-Bodalo, I, 2022)
"Exencephaly/anencephaly is one of the leading causes of neonatal mortality and the most extreme open neural tube defect with no current treatments and limited mechanistic understanding."1.51Cell necrosis, intrinsic apoptosis and senescence contribute to the progression of exencephaly to anencephaly in a mice model of congenital chranioschisis. ( Duru, S; Fernandez-Alonso, I; Fernandez-Martin, A; Figueira, RL; Marotta, M; Oria, M; Peiro, JL; Sbragia, L; Scorletti, F; Shaaban, AF; Turner, LE, 2019)
" Furthermore, it was possible to discriminate toxicants acting at different time points during embryonic development and, therefore, responsible for distinct adverse effects on neural tube formation."1.51Accuracy, discriminative properties and reliability of a human ESC-based in vitro toxicity assay to distinguish teratogens responsible for neural tube defects. ( De Geyter, C; Feutz, AC, 2019)
"Significant decreases in pregnancy weight gain and the number of live fetuses were observed when VPA was administered at the high dose, whereas the percentage of exencephalic fetuses was significantly increased in VPA treated compared with an equivalent VCD dosage group."1.51Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. ( Bialer, M; Cabrera, RM; Finnell, RH; Lin, YL; Wlodarczyk, BJ, 2019)
"If these data translate to the overall transport and subsequent bioavailability of folates, noncompetitive inhibition of the folate receptors by VPA may serve to lower the bioavailable folates in VPA treated mothers."1.40Brief report novel mechanism for valproate-induced teratogenicity. ( Fathe, K; Finnell, RH; Palacios, A, 2014)
" Comparative pharmacokinetic analysis showed that α-Cl-TMCD is less susceptible to liver first-pass effect than α-F-TMCD because of lower total (metabolic) clearance and liver extraction ratio."1.36Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. ( Bialer, M; Finnell, RH; Hen, N; Kaufmann, D; Pessah, N; Wlodarczyk, B; Yagen, B, 2010)
" No stereoselective pharmacokinetics was observed following intraperitoneal dosing of racemic-VCU to rats."1.36Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ( Bialer, M; Finnell, RH; Schurig, V; Shimshoni, JA; Wlodarczyk, B; Yagen, B, 2010)
" It showed a beneficial pharmacokinetic profile in rats, having a high oral bioavailability of 75% and satisfactory values of clearance and volume of distribution."1.34Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. ( Bialer, M; Finnell, RH; Lamb, JG; Sobol, E; White, HS; Wlodarczyk, BJ; Yagen, B, 2007)
"Non-treated homozygous polydactyly/arhinencephaly (Pdn/Pdn) mouse fetuses exhibited exencephaly in 16."1.33Exencephaly induction by valproic acid in the genetic polydactyly/arhinencephaly mouse, Pdn/Pdn. ( Katagiri, R; Maekawa, M; Naruse, I; Ohta, K; Ueta, E, 2005)
"Valproic acid (VPA) is an anticonvulsant drug that is widely used therapeutically for a variety of neurological conditions."1.33Myo-inositol enhances teratogenicity of valproic acid in the mouse. ( Finnell, RH; Giavini, E; Massa, V; Wlodarczyk, B, 2006)
"Valproic acid (VPA) is an antiepileptic drug used clinically."1.32Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. ( Emmanouil-Nikoloussi, EN; Foroglou, NG; Kerameos-Foroglou, CH; Thliveris, JA, 2004)
"Significant increases in fetal loss and exencephaly rate were observed with VPA at 800 mg/kg compared to the vehicle control."1.32Amidic modification of valproic acid reduces skeletal teratogenicity in mice. ( Aoki, Y; Bialer, M; Fujiwara, M; Kurihara, H; Okada, A, 2004)
"PTA significantly reduced VPA-induced exencephaly, while none of the other external malformations such as open eyelid or skeletal malformations such as fused, absent, or bifurcated ribs and fused thoracic vertebrae and fused sternebrae were reduced."1.29Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). ( Nagao, T; Sato, M; Shirota, M, 1995)
"Fetuses were examined for exencephaly, resorption, and fetal weight retardation on day 18 of gestation."1.28Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. ( Elmazar, MM; Nau, H, 1992)
" Using whole rat embryo cultures, the simultaneous addition of methionine and sodium valproate to the medium provided no protection from neural tube defects, nor did the addition of methionine to a medium of serum obtained from rats previously dosed with sodium valproate."1.28Methionine decreases the embryotoxicity of sodium valproate in the rat: in vivo and in vitro observations. ( Klein, NW; Nosel, PG, 1992)
"The rate of neural tube defects (exencephaly) produced by the S-enantiomer was about 4 times higher than that produced by the R-enantiomer."1.28Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. ( Hauck, RS; Nau, H, 1989)
"Phenobarbital pretreatment of the dams (previously shown to reduce VPA serum concentrations and induce the omega- and omega-1 oxidation pathways) reduced the embryotoxicity of VPA."1.27Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen. ( Nau, H, 1986)
" It was found that both the dosage and timing of VPA administration were crucial in the development of lesions which are similar to human spina bifida aperta."1.27New animal model for the study of neural tube defects. ( McCollough, D; Michejda, M, 1987)
"VPA-induced exencephaly in mice may provide an animal model to further investigate biochemical markers for prenatal diagnosis of neural tube defects."1.27Amniotic fluid cholinesterase of valproate-induced exencephaly in the mouse: an animal model for prenatal diagnosis of neural tube defects. ( Elmazar, MM; Spielmann, H; Vogel, R, 1988)

Research

Studies (125)

TimeframeStudies, this research(%)All Research%
pre-199021 (16.80)18.7374
1990's30 (24.00)18.2507
2000's35 (28.00)29.6817
2010's30 (24.00)24.3611
2020's9 (7.20)2.80

Authors

AuthorsStudies
Hen, N5
Bialer, M12
Wlodarczyk, B7
Finnell, RH20
Yagen, B9
Hansen, JM1
Lucas, SM1
Ramos, CD1
Green, EJ1
Nuttall, DJ1
Clark, DS1
Marchant, ED1
Hancock, CR1
Piorczynski, TB1
Błaszczyk, B1
Miziak, B1
Pluta, R1
Czuczwar, SJ1
Rhinn, M1
Zapata-Bodalo, I1
Klein, A1
Plassat, JL1
Knauer-Meyer, T1
Keyes, WM1
Guan, Z1
Liang, Y1
Wang, X1
Zhu, Z1
Yang, A1
Li, S1
Yu, J1
Niu, B1
Wang, J1
Takla, TN1
Luo, J1
Sudyk, R1
Huang, J1
Walker, JC1
Vora, NL1
Sexton, JZ1
Parent, JM1
Tidball, AM1
Feutz, AC1
De Geyter, C1
Oria, M1
Duru, S1
Figueira, RL1
Scorletti, F1
Turner, LE1
Fernandez-Alonso, I1
Fernandez-Martin, A1
Marotta, M1
Sbragia, L1
Shaaban, AF1
Peiro, JL1
Shafique, S2
Winn, LM7
Reynolds, EH1
Green, R1
Muhsen, M1
Youngs, J1
Riu, A1
Gustafsson, JÅ1
Kondamadugu, VS1
Garyfalidis, E1
Bondesson, M1
Patel, N1
Viguera, AC1
Baldessarini, RJ1
Hughes, A1
Greene, NDE1
Copp, AJ1
Galea, GL1
Sher, J1
Frank, JW1
Doi, L1
de Caestecker, L1
Lin, YL1
Cabrera, RM2
Wlodarczyk, BJ4
Turgut, U1
Kazan, S1
Cakin, H1
Ozak, A1
Onishi, Y1
Okada, A4
Noyori, H2
Okamura, A1
Fujiwara, M4
Denny, KJ1
Jeanes, A1
Fathe, K2
Taylor, SM1
Woodruff, TM1
Shekh-Ahmad, T1
McDonough, JH1
Hsieh, CL1
Chen, KC1
Ding, CY1
Tsai, WJ1
Wu, JF1
Peng, CC1
Palacios, A1
Tiboni, GM1
Ponzano, A1
Balon, R1
Riba, M2
Gotlib, D1
Perelstein, E1
Kurlander, J1
Zivin, K1
Muzik, M1
Akimova, D1
Lin, Y1
Ross, ME1
Chen, Q1
Gross, SS1
Jergil, M2
Kultima, K2
Gustafson, AL3
Dencker, L3
Stigson, M3
Ornoy, A1
Bozhinov, P1
Bozhinova, C1
Markova, C1
Martínez-Frías, ML1
Shimshoni, JA4
Schurig, V1
Tung, EW3
Pessah, N3
Kaufmann, D1
de Jong, E1
Doedée, AM1
Reis-Fernandes, MA1
Nau, H15
Piersma, AH1
Kim, KC2
Kim, P2
Go, HS1
Choi, CS1
Yang, SI1
Cheong, JH1
Shin, CY2
Ko, KH1
Forsberg, M1
Salter, H1
Stockling, K1
Umur, AS1
Selcuki, M1
Bursali, A1
Umur, N1
Kara, B1
Vatansever, HS1
Duransoy, YK1
Mallela, M1
Hrubec, T1
Park, JH1
Kwon, KJ1
Kim, HJ1
Lee, JM1
Kim, HY1
Han, SH1
Escalona-Cardoso, GN1
Paniagua-Castro, N1
Pérez-Pastén, R1
Chamorro-Cevallos, G1
Davidson, DL1
Padmanabhan, R2
Shafiullah, MM1
Yerby, MS1
Duchowny, M1
Spiegelstein, O1
Merriweather, MY1
Wicker, NJ1
Kurihara, H1
Aoki, Y2
Lundberg, YW1
Greer, KA1
Zhao, J1
Garg, R1
Emmanouil-Nikoloussi, EN1
Foroglou, NG1
Kerameos-Foroglou, CH1
Thliveris, JA1
Nyström, AM1
Scholz, B1
Alsdorf, R1
Wyszynski, DF1
Kushima, K1
Dawson, JE1
Raymond, AM1
Maekawa, M1
Ohta, K1
Katagiri, R1
Ueta, E1
Naruse, I2
Defoort, EN1
Kim, PM1
Eikel, D1
Hoffmann, K1
Zoll, K1
Lampen, A1
Massa, V1
Giavini, E1
Verrotti, A1
Tana, M1
Pelliccia, P1
Chiarelli, F1
Latini, G1
Shafiullah, M1
Benedict, S1
Nagelkerke, N1
Sobol, E1
Lamb, JG1
White, HS1
Hrubec, TC1
Yan, M1
Ye, K1
Salafia, CM1
Holladay, SD2
Candito, M1
Naimi, M1
Boisson, C1
Rudigoz, JC1
Gaucherand, P1
Guéant, JL1
Luton, D1
Van Obberghen, E1
Singh, NK1
Nagendra, S1
Robert, E1
Guibaud, P1
Leck, I1
Philbert, A1
Pedersen, B1
Graf, WD1
Pippenger, CE1
Shurtleff, DB1
Oakeshott, P1
Hunt, G1
Guest, I1
Buttar, HS1
Smith, S1
Varma, DR1
Thurston, JH1
Hauhart, RE1
Van Waes, M1
Bennett, GD6
Eberwine, JH2
Clayton-Smith, J1
Donnai, D1
Ehlers, K2
Elmazar, MM3
Sato, M1
Shirota, M1
Nagao, T1
Espinasse, M1
Manouvrier, S1
Boute, O1
Farriaux, JP1
Ubeda, N1
Alonso, E1
Martín-Rodríguez, JC1
Varela-Moreiras, G1
Puerta, J1
Pérez-Miguelsanz, J1
Wlodarczyk, BC2
Craig, JC3
Calvin, JA1
Piedrahita, JA2
Hishida, R1
Koren, G1
Kennedy, D1
Craig, J1
Morrison, P1
Morrow, J1
Patterson, V1
Miranda, RC1
Mackler, SA1
Basu, A1
Wezeman, FH1
Al Deeb, S1
Al Moutaery, K1
Arshaduddin, M1
Tariq, M1
Gelineau-van Waes, J1
Barber, RC1
Shaw, GM1
Lammer, EJ1
Sharova, L1
Smith, BJ1
Gogal, RM1
Ward, DL1
Blaylock, BL1
Kozma, C1
Duncan, S1
Mercho, S1
Lopes-Cendes, I1
Seni, MH1
Benjamin, A1
Dubeau, F1
Andermann, F1
Andermann, E1
Isojärvi, J1
Oberemm, A1
Kirschbaum, F1
Nosel, PG1
Klein, NW1
Chadwick, D1
Lindhout, D2
Omtzigt, JG1
Cornel, MC1
Wegner, C3
Kelly, PG1
Regan, CM1
Hauck, RS2
Orrell, RW1
Hansen, DK1
Grafton, TF1
Seegmiller, RE1
Harris, C2
Luchtel, DL1
Juchau, MR2
Markovitz, PJ1
Calabrese, JR1
Schmidt, D1
Weinbaum, PJ1
Cassidy, SB1
Vintzileos, AM1
Campbell, WA1
Ciarleglio, L1
Nochimson, DJ1
Löscher, W1
Brown, EG1
Trotz, M1
Michejda, M1
McCollough, D1
Stark, KL1
Collins, MD1
Scott, WJ1
Vogel, R1
Spielmann, H1
Karras, SB1
Mohl, VK1
Tein, I1
MacGregor, DL1
Garden, AS1
Benzie, RJ1
Hutton, EM1
Gare, DJ1
Wolf, H1
Leschot, NJ1

Reviews

12 reviews available for valproic acid and Acrania

ArticleYear
Epilepsy in Pregnancy-Management Principles and Focus on Valproate.
    International journal of molecular sciences, 2022, Jan-25, Volume: 23, Issue:3

    Topics: Abnormalities, Drug-Induced; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism

2022
Valproate and folate: Congenital and developmental risks.
    Epilepsy & behavior : E&B, 2020, Volume: 108

    Topics: Anticonvulsants; Brain; Female; Folic Acid; Humans; Nervous System Malformations; Neural Tube Defect

2020
Neural tube defects, folate, and immune modulation.
    Birth defects research. Part A, Clinical and molecular teratology, 2013, Volume: 97, Issue:9

    Topics: Anticonvulsants; Autoantibodies; Chemokine CCL2; Complement System Proteins; Female; Folate Receptor

2013
Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:4

    Topics: Abnormalities, Drug-Induced; Contraception Behavior; Female; Folic Acid; Guideline Adherence; Humans

2016
Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
    Reproductive toxicology (Elmsford, N.Y.), 2009, Volume: 28, Issue:1

    Topics: Abnormalities, Drug-Induced; Adolescent; Animals; Anticonvulsants; Autistic Disorder; Child; Child D

2009
Potency ranking of valproic acid analogues as to inhibition of cardiac differentiation of embryonic stem cells in comparison to their in vivo embryotoxicity.
    Reproductive toxicology (Elmsford, N.Y.), 2011, Volume: 31, Issue:4

    Topics: Abnormalities, Drug-Induced; Animal Testing Alternatives; Animals; Cell Differentiation; Cell Line;

2011
Management issues for women with epilepsy: neural tube defects and folic acid supplementation.
    Neurology, 2003, Sep-01, Volume: 61, Issue:6 Suppl 2

    Topics: Adult; Animals; Anticonvulsants; Carbamazepine; Cleft Lip; Cleft Palate; Epilepsy; Female; Folic Aci

2003
Teratogenicity of sodium valproate.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Animals; Autistic Disorder; Cleft Lip;

2005
Recent advances on neural tube defects with special reference to Valproic Acid.
    Endocrine, metabolic & immune disorders drug targets, 2006, Volume: 6, Issue:1

    Topics: Adult; Animals; Anticonvulsants; Epilepsy; Epoxide Hydrolases; Female; Folic Acid; Folic Acid Defici

2006
Valproic acid-induced neural tube defects.
    Ciba Foundation symposium, 1994, Volume: 181

    Topics: Animals; Embryo, Mammalian; Folic Acid; Humans; Neural Tube Defects; Species Specificity; Structure-

1994
Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.
    American journal of medical genetics, 2001, Jan-15, Volume: 98, Issue:2

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Epilepsy; Face; Female

2001
Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
    Pharmacology & toxicology, 1991, Volume: 69, Issue:5

    Topics: Abnormalities, Drug-Induced; Animals; Disease Models, Animal; Female; Humans; Maternal-Fetal Exchang

1991

Other Studies

113 other studies available for valproic acid and Acrania

ArticleYear
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
    Journal of medicinal chemistry, 2010, May-27, Volume: 53, Issue:10

    Topics: Anilides; Animals; Anticonvulsants; Convulsants; Electroshock; Mice; Neural Tube Defects; Pentylenet

2010
Valproic acid promotes SOD2 acetylation: a potential mechanism of valproic acid-induced oxidative stress in developing systems.
    Free radical research, 2021, Volume: 55, Issue:11-12

    Topics: Acetylation; Antioxidants; Female; Glutathione; Glutathione Disulfide; Humans; Neural Tube Defects;

2021
Aberrant induction of p19Arf-mediated cellular senescence contributes to neurodevelopmental defects.
    PLoS biology, 2022, Volume: 20, Issue:6

    Topics: Animals; Autism Spectrum Disorder; Cellular Senescence; Female; Mice; Microcephaly; Neural Tube Defe

2022
Unraveling the Mechanisms of Clinical Drugs-Induced Neural Tube Defects Based on Network Pharmacology and Molecular Docking Analysis.
    Neurochemical research, 2022, Volume: 47, Issue:12

    Topics: Animals; Anticonvulsants; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; ErbB Recept

2022
A Shared Pathogenic Mechanism for Valproic Acid and
    Cells, 2023, Jun-23, Volume: 12, Issue:13

    Topics: Anencephaly; Animals; Brain; Female; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Knockout;

2023
Accuracy, discriminative properties and reliability of a human ESC-based in vitro toxicity assay to distinguish teratogens responsible for neural tube defects.
    Archives of toxicology, 2019, Volume: 93, Issue:8

    Topics: Embryonic Development; Embryonic Stem Cells; Humans; Mycophenolic Acid; Neural Tube Defects; Ochrato

2019
Cell necrosis, intrinsic apoptosis and senescence contribute to the progression of exencephaly to anencephaly in a mice model of congenital chranioschisis.
    Cell death & disease, 2019, 09-26, Volume: 10, Issue:10

    Topics: Amniotic Fluid; Anencephaly; Animals; Apoptosis; Brain; Caspase 3; Caspase 9; Cellular Senescence; C

2019
Gestational exposure to valproic acid upregulates total Stat3 protein expression while downregulating phosphorylated Stat3 in CD-1 mouse embryos with neural tube defects.
    Birth defects research, 2020, 04-15, Volume: 112, Issue:7

    Topics: Animals; Female; Mice; Neural Tube Defects; Neurulation; Pregnancy; STAT3 Transcription Factor; Tera

2020
Role of Cbp, p300 and Akt in valproic acid induced neural tube defects in CD-1 mouse embryos.
    Reproductive toxicology (Elmsford, N.Y.), 2020, Volume: 95

    Topics: Abnormalities, Drug-Induced; Animals; CREB-Binding Protein; Down-Regulation; E1A-Associated p300 Pro

2020
Folic acid supplementation rescues valproic acid-induced developmental neurotoxicity and behavioral alterations in zebrafish embryos.
    Epilepsia, 2021, Volume: 62, Issue:7

    Topics: Animals; Animals, Genetically Modified; Anticonvulsants; Behavior, Animal; Dietary Supplements; Embr

2021
Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:1

    Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dietary Supplements; Female; Fol

2018
Valproic acid disrupts the biomechanics of late spinal neural tube closure in mouse embryos.
    Mechanisms of development, 2018, Volume: 149

    Topics: Animals; Biomechanical Phenomena; Disease Models, Animal; Embryo, Mammalian; Humans; Mice; Neural Tu

2018
Failures in reproductive health policy: overcoming the consequences and causes of inaction.
    Journal of public health (Oxford, England), 2019, 06-01, Volume: 41, Issue:2

    Topics: Female; Fetal Alcohol Spectrum Disorders; Flour; Folic Acid; Food, Fortified; Health Policy; Humans;

2019
Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice.
    Birth defects research, 2019, 08-15, Volume: 111, Issue:14

    Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Female; Fetal Death; Fetus; Mice; Neu

2019
Valproic acid effect on neural tube defects is not prevented by concomitant folic acid supplementation: Early chick embryo model pilot study.
    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2019, Volume: 78

    Topics: Animals; Anticonvulsants; Chick Embryo; Female; Folic Acid; Neural Tube Defects; Pilot Projects; Val

2019
Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2013, Volume: 98, Issue:4

    Topics: Animals; Body Weight; Bone and Bones; Carboxylic Acids; Congenital Abnormalities; Embryo, Mammalian;

2013
Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential.
    Epilepsia, 2014, Volume: 55, Issue:2

    Topics: Amides; Animals; Anticonvulsants; Central Nervous System Stimulants; Male; Mice; Neural Tube Defects

2014
Valproic acid substantially downregulated genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and pax-3, N-acetylcysteine alleviated most of the induced gene alterations in chicken embryo model.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2013, Volume: 54, Issue:4

    Topics: Acetylcysteine; Animals; Avian Proteins; Chick Embryo; Chromatography, High Pressure Liquid; Collage

2013
Brief report novel mechanism for valproate-induced teratogenicity.
    Birth defects research. Part A, Clinical and molecular teratology, 2014, Volume: 100, Issue:8

    Topics: Abnormalities, Drug-Induced; Biological Availability; Cell Line; Embryonic Development; Female; Fola

2014
Prevention of valproic acid-induced neural tube defects by sildenafil citrate.
    Reproductive toxicology (Elmsford, N.Y.), 2015, Aug-15, Volume: 56

    Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Disease Models, Animal; Dose-Response Relation

2015
Should women of childbearing potential be prescribed valproate? a call to action.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:4

    Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Contraception Behavior; Epilepsy; Female; Humans; Inf

2016
Metabolite profiling of whole murine embryos reveals metabolic perturbations associated with maternal valproate-induced neural tube closure defects.
    Birth defects research, 2017, 01-30, Volume: 109, Issue:2

    Topics: Amino Acids; Animals; Carnitine; Dietary Supplements; Disease Models, Animal; Embryo, Mammalian; Fem

2017
Valproic acid-induced deregulation in vitro of genes associated in vivo with neural tube defects.
    Toxicological sciences : an official journal of the Society of Toxicology, 2009, Volume: 108, Issue:1

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Developmen

2009
[Fetal malformations in women with epilepsy].
    Akusherstvo i ginekologiia, 2009, Volume: 48, Issue:1

    Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bulgaria; Carbamazepine; Epilepsy; Female; Humans; Inf

2009
Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
    Neurology, 2009, Jun-09, Volume: 72, Issue:23

    Topics: Abnormalities, Drug-Induced; Anticonvulsants; DNA Damage; Female; Fructose; Histone Deacetylase Inhi

2009
Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative.
    Epilepsia, 2010, Volume: 51, Issue:3

    Topics: Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug

2010
Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2009, Volume: 86, Issue:5

    Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Deep Sedation; Differential T

2009
Epigenetic modifications in valproic acid-induced teratogenesis.
    Toxicology and applied pharmacology, 2010, Nov-01, Volume: 248, Issue:3

    Topics: Abnormalities, Drug-Induced; Acetylation; Animals; Epigenesis, Genetic; Female; Histones; Mice; Neur

2010
Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.
    Epilepsia, 2010, Volume: 51, Issue:10

    Topics: Abnormalities, Drug-Induced; Amides; Analgesics; Animals; Anticonvulsants; Cyclopropanes; Disease Mo

2010
The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats.
    Toxicology letters, 2011, Mar-05, Volume: 201, Issue:2

    Topics: Animals; Anticonvulsants; Autistic Disorder; Disease Models, Animal; Electroshock; Female; Fetus; Gl

2011
Short-time gene expression response to valproic acid and valproic acid analogs in mouse embryonic stem cells.
    Toxicological sciences : an official journal of the Society of Toxicology, 2011, Volume: 121, Issue:2

    Topics: Abnormalities, Drug-Induced; Animals; Butyrates; Cell Line; Embryonic Development; Embryonic Stem Ce

2011
Valproic acid-induced DNA damage increases embryonic p27(KIP1) and caspase-3 expression: a mechanism for valproic-acid induced neural tube defects.
    Reproductive toxicology (Elmsford, N.Y.), 2011, Volume: 32, Issue:3

    Topics: Animals; Anticonvulsants; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cyclin-Dependent Kinase Inhi

2011
Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects.
    Molecular pharmacology, 2011, Volume: 80, Issue:6

    Topics: Animals; Apoptosis; Dose-Response Relationship, Drug; Embryonic Development; Female; Mice; Neural Tu

2011
Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid.
    Epilepsy & behavior : E&B, 2011, Volume: 22, Issue:3

    Topics: Amides; Animals; Anticonvulsants; Convulsants; Disease Models, Animal; Electroshock; Female; Isomeri

2011
Simultaneous folate intake may prevent adverse effect of valproic acid on neurulating nervous system.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2012, Volume: 28, Issue:5

    Topics: Animals; Anticonvulsants; Chick Embryo; Embryonic Development; Folic Acid; Nervous System; Neural Tu

2012
Reduction in valproic acid-induced neural tube defects by maternal immune stimulation: role of apoptosis.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2012, Volume: 95, Issue:4

    Topics: Animals; Apoptosis; Embryo, Mammalian; Female; Immunity; Interferon-gamma; Male; Maternal Exposure;

2012
Effects of Korean red ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 51

    Topics: Animals; Behavior, Animal; Child; Child Development Disorders, Pervasive; Disease Models, Animal; Fe

2013
Spirulina (arthrospira) protects against valproic acid-induced neural tube defects in mice.
    Journal of medicinal food, 2012, Volume: 15, Issue:12

    Topics: Abnormalities, Drug-Induced; Animals; Antioxidants; Female; Fetus; Lipid Peroxidation; Mice; Mice, I

2012
Letter to the editor. Discordant twins for neural tube defect on treatment with sodium valproate.
    Seizure, 2002, Volume: 11, Issue:7

    Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Prenatal Exposure

2002
Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation.
    Congenital anomalies, 2003, Volume: 43, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Brain; Dietary Supplements; Disease Models, Animal; Enzyme Inh

2003
Neurobehavioral teratogenicity in antiepileptic drugs: the new Pandora's box.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1

    Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Developmental Disabilities; Dose-Respons

2004
Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice.
    Birth defects research. Part A, Clinical and molecular teratology, 2003, Volume: 67, Issue:12

    Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carrier Proteins; Diet; Disease Models, Anima

2003
Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2004, Volume: 71, Issue:1

    Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Bone and Bones; Cartilage; Cesarean S

2004
Mapping a chromosomal locus for valproic acid-induced exencephaly in mice.
    Mammalian genome : official journal of the International Mammalian Genome Society, 2004, Volume: 15, Issue:5

    Topics: Animals; Anticonvulsants; Chromosome Mapping; Crosses, Genetic; Female; Genetic Predisposition to Di

2004
Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study.
    Morphologie : bulletin de l'Association des anatomistes, 2004, Volume: 88, Issue:280

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Female; Fetus; Gestational Age; Growt

2004
Valproic acid teratogenicity: a toxicogenomics approach.
    Environmental health perspectives, 2004, Volume: 112, Issue:12

    Topics: Animals; Anticonvulsants; Apoptosis; Biological Assay; Biomarkers; Cell Culture Techniques; Embryoni

2004
Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice.
    Birth defects research. Part A, Clinical and molecular teratology, 2005, Volume: 73, Issue:4

    Topics: Abnormalities, Drug-Induced; Amides; Animals; Embryo, Mammalian; Female; Gene Expression; Gene Expre

2005
Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice.
    Toxicology and applied pharmacology, 2006, Mar-01, Volume: 211, Issue:2

    Topics: Animals; Anticonvulsants; bcl-2-Associated X Protein; Dose-Response Relationship, Drug; Female; Feta

2006
Exencephaly induction by valproic acid in the genetic polydactyly/arhinencephaly mouse, Pdn/Pdn.
    Congenital anomalies, 2005, Volume: 45, Issue:4

    Topics: Abnormalities, Multiple; Animals; Craniofacial Abnormalities; Down-Regulation; Fibroblast Growth Fac

2005
Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects.
    Molecular pharmacology, 2006, Volume: 69, Issue:4

    Topics: Animals; Blotting, Southern; Cell Death; CHO Cells; Cricetinae; DNA; Neural Tube Defects; Oxidation-

2006
S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates an
    Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:4

    Topics: Abnormalities, Drug-Induced; Animals; Blood-Brain Barrier; Disease Models, Animal; Dose-Response Rel

2006
Myo-inositol enhances teratogenicity of valproic acid in the mouse.
    Birth defects research. Part A, Clinical and molecular teratology, 2006, Volume: 76, Issue:3

    Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anticonvulsants; Drug Synergism; Embryo

2006
Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos.
    European journal of nutrition, 2006, Volume: 45, Issue:6

    Topics: Abnormalities, Drug-Induced; Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Dru

2006
Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide.
    Epilepsy research, 2007, Volume: 73, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Cyclopropanes; Female; Male; Mice; Mutagenesi

2007
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma.
    The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology, 2006, Volume: 288, Issue:12

    Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Animals; Anticonvulsants; Dose-Response Relatio

2006
Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect.
    Birth defects research. Part A, Clinical and molecular teratology, 2007, Volume: 79, Issue:1

    Topics: Adult; Anticonvulsants; Epilepsy; Female; Folic Acid; Genetic Predisposition to Disease; Homocystein

2007
Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.
    Epilepsia, 2008, Volume: 49, Issue:7

    Topics: Animals; Anticonvulsants; Behavior, Animal; Electrodes, Implanted; Half-Life; Hippocampus; Kindling,

2008
Reversible neutrophil abnormalities related to supratherapeutic valproic acid levels.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:5

    Topics: Anticonvulsants; Humans; Male; Middle Aged; Neural Tube Defects; Neutrophils; Valproic Acid

2008
Maternal valproic acid and congenital neural tube defects.
    Lancet (London, England), 1982, Oct-23, Volume: 2, Issue:8304

    Topics: Epilepsy; Female; Humans; Maternal-Fetal Exchange; Neural Tube Defects; Pregnancy; Valproic Acid

1982
Sodium valproate and neural tube defects.
    Lancet (London, England), 1982, Dec-04, Volume: 2, Issue:8310

    Topics: Adult; Epilepsy, Tonic-Clonic; Female; Humans; Infant, Newborn; Maternal-Fetal Exchange; Meningocele

1982
Spina bifida and anencephaly: fewer patients, more problems.
    British medical journal (Clinical research ed.), 1983, May-28, Volume: 286, Issue:6379

    Topics: Abnormalities, Drug-Induced; Anencephaly; Female; Humans; Infant, Newborn; Neural Tube Defects; Preg

1983
[Fertile women and valproate. Reactions to information about the possible teratogenic effect].
    Ugeskrift for laeger, 1984, Jul-02, Volume: 146, Issue:27

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Female; Humans; Neural Tube Defects; Pregnancy; Risk

1984
Erythrocyte antioxidant enzyme activities in children with myelomeningocele.
    Developmental medicine and child neurology, 1995, Volume: 37, Issue:10

    Topics: Adolescent; Adult; Child; Child, Preschool; Epilepsy; Erythrocytes; Female; Glutathione Peroxidase;

1995
Prevention of neural tube defects.
    Lancet (London, England), 1994, Jan-08, Volume: 343, Issue:8889

    Topics: Abnormalities, Drug-Induced; Carbamazepine; Female; Folic Acid; Humans; Neural Tube Defects; Pregnan

1994
Evaluation of the rat embryo culture system as a predictive test for human teratogens.
    Canadian journal of physiology and pharmacology, 1994, Volume: 72, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Captopril; Diphenhydramine; DNA; Embryo, Mammalian; False Nega

1994
Vitamins to prevent neural-tube defects.
    The New England journal of medicine, 1993, Jun-03, Volume: 328, Issue:22

    Topics: Epilepsy; Female; Humans; Neural Tube Defects; Pantothenic Acid; Pregnancy; Pregnancy Complications;

1993
Lack of concordance between heat shock proteins and the development of tolerance to teratogen-induced neural tube defects.
    Developmental genetics, 1993, Volume: 14, Issue:2

    Topics: Animals; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Female; Gene Expression; Gene

1993
Fetal valproate syndrome.
    Journal of medical genetics, 1995, Volume: 32, Issue:9

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Epilepsy; Face; Female; Human

1995
Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics.
    The Journal of nutrition, 1996, Volume: 126, Issue:1

    Topics: Animals; Anticonvulsants; Disease Models, Animal; Embryonic and Fetal Development; Female; Incidence

1996
Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I).
    Teratology, 1995, Volume: 52, Issue:3

    Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Embryo, Mammalian; Eyelids; F

1995
[Embryofetopathy due to valproate: a pathology only little known. Apropos of 4 cases].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1996, Volume: 3, Issue:9

    Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child, Preschool; Cleft Lip; Epilepsy; Face; Female; F

1996
Valproate-induced developmental modifications maybe partially prevented by coadministration of folinic acid and S-adenosylmethionine.
    The International journal of developmental biology, 1996, Volume: Suppl 1

    Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Female; Fetus; Leucovorin; Li

1996
Valproic acid-induced changes in gene expression during neurulation in a mouse model.
    Teratology, 1996, Volume: 54, Issue:6

    Topics: Animals; Gene Expression; Mice; Mice, Inbred Strains; Models, Biological; Multivariate Analysis; Ner

1996
Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model.
    American journal of medical genetics, 1997, Jun-13, Volume: 70, Issue:3

    Topics: 5,10-Methylenetetrahydrofolate Reductase (FADH2); Animals; Data Interpretation, Statistical; Mice; M

1997
VPA-induced neural tube defects in mice. I. Altered metabolism of sulfur amino acids and glutathione.
    Teratogenesis, carcinogenesis, and mutagenesis, 1998, Volume: 18, Issue:2

    Topics: Abnormalities, Drug-Induced; Amino Acids; Animals; Anticonvulsants; Female; Folic Acid; Glutathione;

1998
Safe use of valproic acid during pregnancy.
    Canadian family physician Medecin de famille canadien, 1999, Volume: 45

    Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complica

1999
Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate.
    Seizure, 1999, Volume: 8, Issue:4

    Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy, Generalized; Female; Folic Acid; Huma

1999
Ribonucleotide reductase subunit R1: a gene conferring sensitivity to valproic acid-induced neural tube defects in mice.
    Teratology, 2000, Volume: 61, Issue:4

    Topics: Animals; Anticonvulsants; Embryonic and Fetal Development; Female; Gene Expression Regulation, Devel

2000
Developmental toxicity of valproic acid during embryonic chick vertebral chondrogenesis.
    Spine, 2000, Sep-01, Volume: 25, Issue:17

    Topics: Abnormalities, Drug-Induced; Age Factors; Aggrecans; Animals; Cell Survival; Chick Embryo; Chondroge

2000
Vitamin E decreases valproic acid induced neural tube defects in mice.
    Neuroscience letters, 2000, Oct-13, Volume: 292, Issue:3

    Topics: Administration, Oral; Animals; Crown-Rump Length; Dose-Response Relationship, Drug; Female; Fetal We

2000
Genetic basis of susceptibility to environmentally induced neural tube defects.
    Annals of the New York Academy of Sciences, 2000, Volume: 919

    Topics: Animals; Carrier Proteins; Cell Cycle; Disease Models, Animal; DNA Fingerprinting; Embryonic and Fet

2000
Nonspecific stimulation of the maternal immune system. I. Effects On teratogen-induced fetal malformations.
    Teratology, 2000, Volume: 62, Issue:6

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adjuvants, Immunologic; Animals; BCG Vaccine;

2000
Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality.
    Epilepsia, 2001, Volume: 42, Issue:6

    Topics: Adult; Anticonvulsants; Epilepsy; Female; Genetic Predisposition to Disease; Gravidity; Humans; Neur

2001
[The dangers of valproate in women].
    Duodecim; laaketieteellinen aikakauskirja, 1998, Volume: 114, Issue:9

    Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cholesterol, HDL; Epilepsy; Female; Humans; Hyperandro

1998
Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice.
    Teratogenesis, carcinogenesis, and mutagenesis, 1992, Volume: 12, Issue:5

    Topics: Abnormalities, Drug-Induced; Animals; Drug Synergism; Encephalocele; Female; Folic Acid; Methotrexat

1992
Valproic acid induced abnormal development of the central nervous system of three species of amphibians: implications for neural tube defects and alternative experimental systems.
    Teratogenesis, carcinogenesis, and mutagenesis, 1992, Volume: 12, Issue:6

    Topics: Abnormalities, Drug-Induced; Ambystoma mexicanum; Amphibians; Animals; Central Nervous System; Neura

1992
Methionine decreases the embryotoxicity of sodium valproate in the rat: in vivo and in vitro observations.
    Teratology, 1992, Volume: 46, Issue:5

    Topics: Animals; Culture Techniques; Embryo, Mammalian; Embryonic and Fetal Development; Female; Fetal Resor

1992
Neural tube defects in association with epilepsy and its treatment.
    Pharmaceutisch weekblad. Scientific edition, 1992, Jun-19, Volume: 14, Issue:3A

    Topics: Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic Acid

1992
Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs.
    Neurology, 1992, Volume: 42, Issue:4 Suppl 5

    Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant; Infant,

1992
Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis.
    Neurology, 1992, Volume: 42, Issue:4 Suppl 5

    Topics: Animals; Circadian Rhythm; Fatty Acids, Monounsaturated; Female; Fetus; Folic Acid; Leucovorin; Mice

1992
Studies on valproate-induced perturbations of neurulation in the explanted chick embryo.
    Toxicology, 1992, Volume: 71, Issue:1-2

    Topics: Animals; Cells, Cultured; Chick Embryo; Dose-Response Relationship, Drug; Heart; Microscopy, Electro

1992
Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent.
    Reproductive toxicology (Elmsford, N.Y.), 1991, Volume: 5, Issue:6

    Topics: Abnormalities, Drug-Induced; Animals; Chromatography, High Pressure Liquid; Circadian Rhythm; Decidu

1991
Sodium valproate in pregnancy.
    BMJ (Clinical research ed.), 1991, Jul-06, Volume: 303, Issue:6793

    Topics: Epilepsy; Female; Fetal Diseases; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; V

1991
Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro.
    Teratology, 1991, Volume: 43, Issue:6

    Topics: Animals; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fetal Death; In Vitro Techniqu

1991
Morphological differences elicited by two weak acids, retinoic and valproic, in rat embryos grown in vitro.
    Teratology, 1991, Volume: 43, Issue:2

    Topics: Animals; Brain; Branchial Region; Cell Differentiation; Culture Techniques; DNA; Dose-Response Relat

1991
Use of anticonvulsants for manic depression during pregnancy.
    Psychosomatics, 1990,Winter, Volume: 31, Issue:1

    Topics: Bipolar Disorder; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic

1990
Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.
    Toxicology letters, 1989, Volume: 49, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Fatty Acids, Monounsaturated; Female; Mice; Neural Tube Defect

1989
In-utero exposure to valproate and neural tube defects.
    Lancet (London, England), 1986, Jun-14, Volume: 1, Issue:8494

    Topics: Anticonvulsants; Epilepsy; Female; Fetus; Humans; Infant, Newborn; Maternal-Fetal Exchange; Neural T

1986
Prenatal detection of a neural tube defect after fetal exposure to valproic acid.
    Obstetrics and gynecology, 1986, Volume: 67, Issue:3 Suppl

    Topics: Abortion, Therapeutic; Adolescent; Epilepsy; Female; Fetal Diseases; Humans; Hydrocephalus; Meningom

1986
Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1986, Volume: 6, Issue:4

    Topics: Administration, Oral; Animals; Biotransformation; Female; Injections, Intraperitoneal; Injections, S

1986
Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1986, Volume: 6, Issue:4

    Topics: Animals; Anticonvulsants; Female; Mice; Neural Tube Defects; Pregnancy; Protein Binding; Structure-A

1986
Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
    Teratology, 1986, Volume: 33, Issue:1

    Topics: Administration, Oral; Animals; Anticonvulsants; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturat

1986
Prescribing in pregnancy.
    British medical journal (Clinical research ed.), 1987, Jan-17, Volume: 294, Issue:6565

    Topics: Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic Acid

1987
Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse.
    Life sciences, 1987, Jul-06, Volume: 41, Issue:1

    Topics: Animals; Female; Leucovorin; Mice; Neural Tube Defects; Pregnancy; Teratogens; Valproic Acid

1987
New animal model for the study of neural tube defects.
    Zeitschrift fur Kinderchirurgie : organ der Deutschen, der Schweizerischen und der Osterreichischen Gesellschaft fur Kinderchirurgie = Surgery in infancy and childhood, 1987, Volume: 42 Suppl 1

    Topics: Animals; Disease Models, Animal; Female; Gestational Age; Lumbar Vertebrae; Macaca mulatta; Neural T

1987
Glutathione status and the incidence of neural tube defects elicited by direct acting teratogens in vitro.
    Teratology, 1988, Volume: 37, Issue:6

    Topics: 2-Acetylaminofluorene; Animals; Cytochalasin D; Cytochalasins; Female; Glutathione; Hydroxyacetylami

1988
Strain differences in the teratogenicity induced by sodium valproate in cultured mouse embryos.
    Teratology, 1988, Volume: 38, Issue:1

    Topics: Animals; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Injections, Intraperitoneal; M

1988
Amniotic fluid cholinesterase of valproate-induced exencephaly in the mouse: an animal model for prenatal diagnosis of neural tube defects.
    Archives of toxicology, 1988, Volume: 61, Issue:6

    Topics: Amniotic Fluid; Animals; Brain; Cholinesterases; Disease Models, Animal; Female; Fetal Diseases; Mic

1988
Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite.
    Teratology, 1988, Volume: 38, Issue:4

    Topics: Animals; Disease Susceptibility; Fatty Acids, Monounsaturated; Female; Fetal Resorption; Male; Mice;

1988
Possible valproate teratogenicity.
    Archives of neurology, 1985, Volume: 42, Issue:3

    Topics: Abnormalities, Multiple; Epilepsy; Female; Humans; Infant, Newborn; Maternal-Fetal Exchange; Neural

1985
Valproic acid therapy and neural tube defects.
    Canadian Medical Association journal, 1985, Apr-15, Volume: 132, Issue:8

    Topics: Abortion, Induced; Adult; Amniocentesis; Female; Genetic Counseling; Humans; Neural Tube Defects; Pr

1985
Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse.
    Toxicology and applied pharmacology, 1985, Sep-15, Volume: 80, Issue:2

    Topics: Animals; Female; Fetal Resorption; Injections, Subcutaneous; Mice; Neural Tube Defects; Pregnancy; T

1985
[Prenatal diagnosis of neural tube defects in use of valproic acid].
    Nederlands tijdschrift voor geneeskunde, 1985, Sep-28, Volume: 129, Issue:39

    Topics: Female; Humans; Maternal-Fetal Exchange; Neural Tube Defects; Pregnancy; Prenatal Diagnosis; Valproi

1985